Topical administration of mupirocin ointment and fusidic acid in bacterial infection-induced skin diseases.

Junyi Xie, Min Li, Su Yang, Qing Dong
Author Information
  1. Junyi Xie: Department of Dermatology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  2. Min Li: Department of Dermatology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  3. Su Yang: Department of Dermatology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
  4. Qing Dong: Department of Dermatology, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Abstract

Introduction: Bacterial skin diseases have strong virulence to penetrate deep into the skin.
Aim: To evaluate the therapeutic effects of 2% mupirocin ointment and 2% fusidic acid cream on bacterial skin diseases and their safety.
Material and methods: One-hundred patients with bacterial skin diseases treated from May 2021 to May 2024 were randomly divided into a control group and a treatment group ( = 50) and they were given 2% mupirocin ointment and 2% fusidic acid cream, respectively. The skin injury areas, eczema area and severity index (EASI) scores, therapeutic effects and adverse reactions were compared before and after two courses of medication. The antibacterial activities of these two drugs against and were detected by the agar diffusion method.
Results: After treatment, the EASI and itching scores of both groups significantly decreased compared with those before treatment ( = 30.804, 19.018, < 0.001; = 24.594, 12.680, < 0.001), and the treatment group had significantly lower scores than those of the control group ( < 0.05). The overall effective rate of the treatment group (96.00%) was higher than that of the control group (90.00%) ( > 0.05), and the distribution of therapeutic effects of the treatment group was significantly better ( < 0.05). The two groups had similar incidence rates of adverse reactions (χ = 1.0147, = 0.3074) that were remitted without additional therapy. Both mupirocin ointment and fusidic acid cream had clear inhibition zones for , with similar diameters (31.69 ±7.12 mm vs. 31.78 ±6.54 mm, = 0.0949, = 0.9245). However, only fusidic acid cream had an obvious inhibition zone for on reinforced Brucella agar plate.
Conclusions: The therapeutic effects of fusidic acid cream on bacterial skin diseases were superior to those of mupirocin ointment.

Keywords

References

  1. Sci Rep. 2019 Oct 10;9(1):14658 [PMID: 31601845]
  2. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1648-1659 [PMID: 35535625]
  3. Infect Immun. 2021 Mar 17;89(4): [PMID: 33468585]
  4. FEMS Microbiol Ecol. 2020 Jun 1;96(6): [PMID: 32396198]
  5. J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:3-17 [PMID: 37232427]
  6. Dermatol Ther (Heidelb). 2014 Dec;4(2):233-48 [PMID: 25212256]
  7. Arch Immunol Ther Exp (Warsz). 2019 Feb;67(1):1-18 [PMID: 30302512]
  8. Dermatitis. 2023 Sep-Oct;34(5):440-444 [PMID: 36917539]
  9. Indian J Dermatol. 2021 Mar-Apr;66(2):117-125 [PMID: 34188265]
  10. Exp Dermatol. 2021 Oct;30(10):1546-1553 [PMID: 34415635]
  11. J Ethnopharmacol. 2020 Mar 25;250:112443 [PMID: 31790819]
  12. Front Med (Lausanne). 2022 Apr 25;9:861115 [PMID: 35547219]
  13. Trials. 2019 Dec 19;20(1):754 [PMID: 31856900]
  14. Ann Med. 2023;55(2):2267425 [PMID: 37844200]
  15. Des Monomers Polym. 2022 Jun 9;25(1):165-174 [PMID: 35711622]
  16. Front Pharmacol. 2021 Oct 15;12:759220 [PMID: 34721042]
  17. Curr Ther Res Clin Exp. 2022 Dec 24;98:100690 [PMID: 36712177]
  18. BMJ Open. 2019 Oct 28;9(10):e031527 [PMID: 31662391]
  19. Inflamm Regen. 2022 Sep 1;42(1):26 [PMID: 36045395]
  20. Antibiotics (Basel). 2023 Jan 17;12(2): [PMID: 36830098]
  21. Dermatol Ther. 2020 Nov;33(6):e13824 [PMID: 32531105]
  22. Int J Dermatol. 2024 Sep;63(9):1205-1211 [PMID: 38433123]

Word Cloud

Created with Highcharts 10.0.0skin0fusidicacidgroup=diseasesmupirocintreatmentointmentcreambacterialtherapeuticeffects2%<controlscorestwosignificantly05MayEASIadversereactionscomparedagaritchinggroups0011200%similarinhibition31mmIntroduction:BacterialstrongvirulencepenetratedeepAim:evaluatesafetyMaterialmethods:One-hundredpatientstreated20212024randomlydivided50givenrespectivelyinjuryareaseczemaareaseverityindexcoursesmedicationantibacterialactivitiesdrugsdetecteddiffusionmethodResults:decreased308041901824594680loweroveralleffectiverate96higher90>distributionbetterincidenceratesχ101473074remittedwithoutadditionaltherapyclearzonesdiameters69±7vs78±65409499245HoweverobviouszonereinforcedBrucellaplateConclusions:superiorTopicaladministrationinfection-inducedinfections

Similar Articles

Cited By

No available data.